Bio-Rad Laboratories (NYSE:BIO) Stock Gets Price Target Boost from Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Bio-Rad from $390 to $440 and maintained an “outperform” rating, implying 19.08% upside from the stock’s then-current price.
• Bio-Rad’s quarterly results topped expectations: EPS was $2.65 versus $2.23 estimated, and revenue was $656.4 million versus $649.94 million. Revenue rose just 0.5% year over year.
• Analyst sentiment overall remained cautious, with MarketBeat reporting a consensus “Hold” rating and an average target of $366.67; shares fell 2.8% on Thursday to $369.49.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) had its price target boosted by analysts at Royal Bank Of Canada from $390.00 to $440.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical research company's stock. Royal Bank Of Canada's price target would suggest a potential upside of 19.08% from the company's current price.

Several other research analysts have also weighed in on the company. Weiss Ratings raised Bio-Rad Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. Wells Fargo & Company increased their price objective on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. Citigroup raised their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a "hold" rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $366.67.

Bio-Rad Laboratories Trading Down 2.8%

Shares of BIO traded down $10.50 during trading hours on Thursday, hitting $369.49. 224,849 shares of the stock traded hands, compared to its average volume of 305,727. The business has a fifty day moving average of $374.31 and a 200-day moving average of $314.89. Bio-Rad Laboratories has a 1-year low of $236.73 and a 1-year high of $396.23. The firm has a market capitalization of $9.88 billion, a PE ratio of 44.91 and a beta of 1.06. The company has a current ratio of 3.14, a quick ratio of 2.33 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 EPS for the quarter, topping analysts' consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%. The business had revenue of $656.40 million during the quarter, compared to analysts' expectations of $649.94 million. During the same period in the previous year, the firm earned $2.26 earnings per share. The firm's quarterly revenue was up .5% compared to the same quarter last year. Analysts expect that Bio-Rad Laboratories will post 9.71 EPS for the current year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several large investors have recently modified their holdings of BIO. Root Financial Partners LLC bought a new position in Bio-Rad Laboratories in the 3rd quarter valued at approximately $34,000. Integrated Wealth Concepts LLC purchased a new position in Bio-Rad Laboratories during the second quarter valued at $27,000. Hollencrest Capital Management purchased a new stake in Bio-Rad Laboratories in the 1st quarter worth approximately $28,000. Nykredit A S bought a new position in Bio-Rad Laboratories in the 2nd quarter worth $118,000. Finally, Signaturefd LLC boosted its stake in shares of Bio-Rad Laboratories by 51.7% in the third quarter. Signaturefd LLC now owns 437 shares of the medical research company's stock worth $165,000 after acquiring an additional 149 shares during the period. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories News Summary

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported Q3 earnings of $2.65 per share, above estimates, while revenue of $656.4 million also exceeded expectations. EPS rose from $2.26 a year earlier, though revenue increased just 0.5%. Article: Bio-Rad Laboratories Q3 Earnings Top Estimates
• Positive Sentiment: The company expanded its oncology assay menu for QX700 digital droplet PCR systems, adding to its product offering. Article: Bio-Rad Expands Oncology Assay Menu for QX700 ddPCR Systems
• Negative Sentiment: Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to 0.5%, signaling limited near-term sales growth. It did target the upper half of its 10%–12% non-GAAP operating-margin range, which offers some support, but the restrained revenue outlook may temper the earnings beat. Article: Bio-Rad Reaffirms 2026 Revenue Growth and Margin Targets

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company's clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.